Control of Moderate or Severe Asthma With 160, 320 and 640 mcg Ciclesonide/Day. A One-year Randomised, Double-blind, Multicenter Trial.

Trial Profile

Control of Moderate or Severe Asthma With 160, 320 and 640 mcg Ciclesonide/Day. A One-year Randomised, Double-blind, Multicenter Trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Ciclesonide (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms CONTRAST
  • Sponsors Takeda
  • Most Recent Events

    • 06 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 18 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 04 May 2012 Company (Takeda Global Research and Development Center, Inc) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top